title: [Individualized treatment for ovarian cancer may become possible].
abstract: Epithelial ovarian cancer (EOC) is the most lethal gynecologic malignancy in developed countries. Several promising steps toward individualized therapy have been taken recently due to increased knowledge of molecular biology. Multidisciplinary conferences for treatment planning and the centralization to tertiary surgical centers improve quality of surgery and survival. The primary treatment of EOC is radical surgery followed by adjuvant chemotherapy with carboplatin and paclitaxel. Bevacizumab added to the chemotherapy and used as maintenance treatment is standard in the primary treatment of patients with residual tumor or inoperable patients. The PARP inhibitor olaparib is recommended as maintenance treatment of women with platinum sensitive relapsed BRCA mutated high-grade serous EOC who have responded to platinum-based chemotherapy. BRCA testing should be offered to women with EOC. In platinum-resistant recurrence addition of bevacizumab to chemotherapy should be considered.
authors.affiliation: Kvinnokliniken - Universitetssjukhuset Linköping, Sweden Kvinnokliniken - IKE Linköping, Sweden.
authors.forename: Preben
authors.initials: P
authors.lastname: Kjölhede
authors.affiliation: Göteborgs Universitet - Obstetrik och Gynekologi Göteborg, Sweden Göteborgs Universitet - Obstetrik och Gynekologi Göteborg, Sweden.
authors.forename: Pernilla
authors.initials: P
authors.lastname: Dahm-Kähler
authors.affiliation: Uppsala University. Akademiska sjukhuset - Dept of Oncology Uppsala, Sweden Uppsala Univeristy. Akademiska sjukhuset - Dept of Oncology Uppsala, Sweden.
authors.forename: Bengt
authors.initials: B
authors.lastname: Tholander
authors.affiliation: Onkologiska kliniken - IKE, Linköping University Linköping, Sweden Department of Clinical and Experimental Medicine, Linköping University - Department of Oncology Linköping, Sweden.
authors.forename: Elisabeth
authors.initials: E
authors.lastname: Åvall Lundqvist
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D005260:Female; D006801:Humans; D009367:Neoplasm Staging; D009375:Neoplasms, Glandular and Epithelial / Q000145:classification / Q000188:drug therapy / Q000401:mortality / Q000601:surgery; D010051:Ovarian Neoplasms / Q000145:classification / Q000188:drug therapy / Q000401:mortality / Q000601:surgery; D000067856:Poly(ADP-ribose) Polymerase Inhibitors / Q000627:therapeutic use; D057285:Precision Medicine / Q000639:trends
chemical_list: D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D000067856:Poly(ADP-ribose) Polymerase Inhibitors